Overview
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
Status:
Completed
Completed
Trial end date:
2019-12-17
2019-12-17
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in Patients with acne vulgarisPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sol-Gel Technologies, Ltd.
Criteria
Inclusion Criteria:1. Patient must sign an Institutional Review Board (IRB) approved written informed
consent for this study.
2. Male and female 9 years of age and older.
3. Have two (2) or fewer cysts or nodules
Exclusion Criteria:
1. More than two acne nodules or cysts (defined as an inflammatory lesion greater than or
equal to 5 mm in diameter).
2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.)
3. History of blood dyscrasia (e.g., leukemia, haemophilia, sickle cell anemia, multiple
myeloma, etc.)
4. Underlying disease that requires the use of interfering topical or systemic therapy.
5. Other dermatological conditions that require the use of interfering topical or
systemic therapy or that might interfere with study assessments such as, but not
limited to, atopic dermatitis, perioral dermatitis, or rosacea.